Avidity Partners Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Avidity Partners Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Sell	200,000 -49,390	-20%	-$564K	0.35%	30
2026 Q1	$2.77M	Buy	249,390 +43,314	+21%	+$547K	0.56%	20
2025 Q4	$3.42M	Sell	206,076 -99,924	-33%	-$1.43M	0.99%	21
2025 Q3	$3.6M	Sell	306,000 -758,500	-71%	-$7.83M	0.82%	30
2025 Q2	$10.2M	Buy	1,064,500 +264,500	+33%	+$1.46M	2.03%	16
2025 Q1	$5.02M	Sell	800,000 -590,100	-42%	-$3.58M	0.96%	38
2024 Q4	$11.3M	Sell	1,390,100 -414,393	-23%	-$5.13M	1.11%	37
2024 Q3	$32.6M	Buy	1,804,493 +184,493	+11%	+$2.58M	1.66%	24
2024 Q2	$16.7M	Sell	1,620,000 -115,000	-7%	-$1.18M	0.71%	51
2024 Q1	$18.4M	Buy	1,735,000 +13,420	+0.8%	+$114K	0.59%	53
2023 Q4	$15.7M	Buy	1,721,580 +104,280	+6%	+$898K	0.57%	51
2023 Q3	$16.8M	Sell	1,617,300 -332,400	-17%	-$4.56M	0.68%	55
2023 Q2	$27.9M	Sell	1,949,700 -98,900	-5%	-$1.14M	0.98%	42
2023 Q1	$14.6M	Buy	2,048,600 +148,600	+8%	+$1.31M	0.49%	61
2022 Q4	$21.3M	Sell	1,900,000 -6,800	-0.4%	-$70.1K	0.46%	50
2022 Q3	$21.1M	Sell	1,906,800 -13,000	-0.7%	-$124K	0.43%	52
2022 Q2	$16.2M	Sell	1,919,800 -26,200	-1%	-$269K	0.37%	41
2022 Q1	$26.5M	Buy	1,946,000 +50,000	+3%	+$808K	0.55%	46
2021 Q4	$37.3M	Buy	+1,896,000	New	+$44.6M	0.79%	42
2021 Q1	–	Sell	-152,500	Closed	-$5.07M	–	118
2020 Q4	$5.07M	Buy	+152,500	New	+$6.18M	0.16%	81

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Avidity Partners Management's PHAT Position: Q2 2026 in Review

Avidity Partners Management reduced its Phathom Pharmaceuticals (PHAT) stake by 20% in Q2 2026, selling an estimated $564K and leaving 200,000 shares worth $2.17M. The position accounts for 0.35% of the portfolio, ranked #30.

Avidity Partners Management first reported a position in PHAT in Q4 2020 and has held it in 20 quarters since. The position peaked at $37.3M in Q4 2021. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Avidity Partners Management held 200,000 shares of Phathom Pharmaceuticals worth $2.17M as of Q2 2026.
Avidity Partners Management sold 49,390 Phathom Pharmaceuticals shares in Q2 2026, an estimated $564K.
Phathom Pharmaceuticals made up 0.35% of Avidity Partners Management's portfolio in Q2 2026, its #30 holding.
Avidity Partners Management first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
Avidity Partners Management's Phathom Pharmaceuticals position peaked at $37.3M in Q4 2021.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.